Axsome Therapeutics, Inc. (AXSM)
205.23
+2.40
(+1.18%)
USD |
NASDAQ |
Sep 02, 11:32
Axsome Therapeutics Research and Development Expense (TTM) : 187.36M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 187.36M |
| March 31, 2026 | 190.82M |
| December 31, 2025 | 182.48M |
| September 30, 2025 | 188.68M |
| June 30, 2025 | 193.58M |
| March 31, 2025 | 193.62M |
| December 31, 2024 | 185.99M |
| September 30, 2024 | 161.78M |
| June 30, 2024 | 145.48M |
| March 31, 2024 | 116.37M |
| December 31, 2023 | 97.48M |
| September 30, 2023 | 81.42M |
| June 30, 2023 | 67.60M |
| March 31, 2023 | 62.84M |
| December 31, 2022 | 57.68M |
| September 30, 2022 | 56.83M |
| June 30, 2022 | 55.18M |
| March 31, 2022 | 53.95M |
| December 31, 2021 | 57.98M |
| September 30, 2021 | 61.61M |
| Date | Value |
|---|---|
| June 30, 2021 | 63.25M |
| March 31, 2021 | 59.29M |
| December 31, 2020 | 70.22M |
| September 30, 2020 | 72.04M |
| June 30, 2020 | 73.09M |
| March 31, 2020 | 73.55M |
| December 31, 2019 | 53.64M |
| September 30, 2019 | 41.59M |
| June 30, 2019 | 31.80M |
| March 31, 2019 | 26.35M |
| December 31, 2018 | 23.50M |
| September 30, 2018 | 20.84M |
| June 30, 2018 | 19.27M |
| March 31, 2018 | 18.72M |
| December 31, 2017 | 19.96M |
| September 30, 2017 | 21.27M |
| June 30, 2017 | 22.37M |
| March 31, 2017 | 22.66M |
| December 31, 2016 | 21.20M |
| September 30, 2016 | 17.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly & Co. | 14.60B |
| Liquidia Corp. | 54.95M |
| Filana Therapeutics, Inc. | 15.66M |
| CorMedix, Inc. | 27.59M |
| Eloxx Pharmaceuticals, Inc. | 6.647M |